Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Declines By 9.0%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a significant drop in short interest in August. As of August 15th, there was short interest totalling 57,300 shares, a drop of 9.0% from the July 31st total of 63,000 shares. Based on an average trading volume of 32,300 shares, the short-interest ratio is presently 1.8 days. Approximately 0.8% of the company’s shares are short sold.

Cocrystal Pharma Price Performance

COCP traded down $0.06 on Tuesday, reaching $1.74. 17,311 shares of the company traded hands, compared to its average volume of 22,127. The stock’s 50 day moving average price is $2.08 and its 200-day moving average price is $1.88. Cocrystal Pharma has a 52-week low of $1.33 and a 52-week high of $3.10. The company has a market cap of $17.70 million, a price-to-earnings ratio of -1.00 and a beta of 1.41.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). As a group, equities research analysts forecast that Cocrystal Pharma will post -1.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price objective on shares of Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, August 22nd.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.